Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Allakos is conducting additional clinical studies to better characterize MGID and assess the disease prevalence in patients with chronic functional gastrointestinal symptoms including those with irritable bowel syndrome, functional dyspepsia, and chronic gastritis.